Lag Time for New Innovative, First-in-Class, Drug Approval in Japan

Early access to novel drugs, regardless of regional differences, is significant for patients worldwide. Although various efforts have been made to reduce the drug lag, it still exists in some regions, including Japan. In this study, we focused on the drug lag of first-in-class drugs in Japan and obt...

Full description

Saved in:
Bibliographic Details
Published in:Biological & pharmaceutical bulletin 2022/04/01, Vol.45(4), pp.477-482
Main Authors: Miyazaki, Takayuki, Komiyama, Michiyuki, Matsumaru, Naoki, Maeda, Hideki, Tsukamoto, Katsura
Format: Article
Language:English
Subjects:
Committees
Drug Approval
Drug development
drug lag
drug price
Drugs
first-in-class drug
Government policy
Humans
Japan
me-too drug
multi-regional clinical trial
Multiple regression analysis
Multivariate Analysis
Statistical analysis
Time Factors
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4828-819736d40cdb28b51c07aacf6dcb23f805c684d67193e460d7f531a3704dd58b3
cites cdi_FETCH-LOGICAL-c4828-819736d40cdb28b51c07aacf6dcb23f805c684d67193e460d7f531a3704dd58b3
container_end_page 482
container_issue 4
container_start_page 477
container_title Biological & pharmaceutical bulletin
container_volume 45
creator Miyazaki, Takayuki
Komiyama, Michiyuki
Matsumaru, Naoki
Maeda, Hideki
Tsukamoto, Katsura
description Early access to novel drugs, regardless of regional differences, is significant for patients worldwide. Although various efforts have been made to reduce the drug lag, it still exists in some regions, including Japan. In this study, we focused on the drug lag of first-in-class drugs in Japan and obtained fundamental information because we considered that first-in-class and me-too drugs are essentially different and should be treated separately. We analyzed 97 first-in-class and 176 me-too drugs in new molecular entity (NME)-approved drugs in Japan and the United States during the fiscal years between 2009 and 2019. Since government policy and the Evaluation Committee on Unapproved or Off-labeled Drugs with High Medical Needs (the Committee) have a huge impact on drug lag, we distinguished NMEs developed at the Committee’s request. First-in-class drugs were developed at the Committee’s request significantly more than the me-too drugs (p = 0.0034). Although it was not statistically significant, the approval lags were 498.0 d for first-in-class drugs and 535.0 d for me-too drugs. Multiple regression analysis showed that multi-regional clinical trial (MRCT) development strategy (p = 0.0043) and foreign origin drugs (p = 0.0072) were a reducing factor and a prolonging factor of drug lag, respectively. In conclusion, the drug lag for first-in-class drug approval was one year. Global drug development using MRCT is one of the most effective development strategies for reducing drug lags.
doi_str_mv 10.1248/bpb.b21-00898
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2646942003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2646942003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4828-819736d40cdb28b51c07aacf6dcb23f805c684d67193e460d7f531a3704dd58b3</originalsourceid><addsrcrecordid>eNpd0DtPwzAUBWALgWgpjKzIEgtDXfxMnLEKlIcqWMpsOY5TUqVJsJMi_j3ugw4stqX76fjqAHBN8IRQLu-zNptklCCMZSJPwJAwHiNBiTgFQ5wQiSIi5ABceL_CGMeYsnMwYIKFV0yHIJ3rJVyUawuLxsE3-w1f6rrZ6K7c2DGclc53qKxRWmnvx_DB9Us4bVsXRAXLGr7qVteX4KzQlbdXh3sEPmaPi_QZzd-fXtLpHBkuqUSSJDGLco5NnlGZCWJwrLUpotxklBUSCxNJnkcxSZjlEc7jQjCiw6Y8z4XM2Ajc7XPD_1-99Z1al97YqtK1bXqvaMSjhFOMWaC3_-iq6V0dttspIjiVIii0V8Y13jtbqNaVa-1-FMFq264K7arQrtq1G_zNIbXP1jY_6r86A0j3YOU7vbRHoF1Xmsru4rhQfHscY49T86mdsjX7BWBFiiQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2646154285</pqid></control><display><type>article</type><title>Lag Time for New Innovative, First-in-Class, Drug Approval in Japan</title><source>Free Full-Text Journals in Chemistry</source><creator>Miyazaki, Takayuki ; Komiyama, Michiyuki ; Matsumaru, Naoki ; Maeda, Hideki ; Tsukamoto, Katsura</creator><creatorcontrib>Miyazaki, Takayuki ; Komiyama, Michiyuki ; Matsumaru, Naoki ; Maeda, Hideki ; Tsukamoto, Katsura</creatorcontrib><description>Early access to novel drugs, regardless of regional differences, is significant for patients worldwide. Although various efforts have been made to reduce the drug lag, it still exists in some regions, including Japan. In this study, we focused on the drug lag of first-in-class drugs in Japan and obtained fundamental information because we considered that first-in-class and me-too drugs are essentially different and should be treated separately. We analyzed 97 first-in-class and 176 me-too drugs in new molecular entity (NME)-approved drugs in Japan and the United States during the fiscal years between 2009 and 2019. Since government policy and the Evaluation Committee on Unapproved or Off-labeled Drugs with High Medical Needs (the Committee) have a huge impact on drug lag, we distinguished NMEs developed at the Committee’s request. First-in-class drugs were developed at the Committee’s request significantly more than the me-too drugs (p = 0.0034). Although it was not statistically significant, the approval lags were 498.0 d for first-in-class drugs and 535.0 d for me-too drugs. Multiple regression analysis showed that multi-regional clinical trial (MRCT) development strategy (p = 0.0043) and foreign origin drugs (p = 0.0072) were a reducing factor and a prolonging factor of drug lag, respectively. In conclusion, the drug lag for first-in-class drug approval was one year. Global drug development using MRCT is one of the most effective development strategies for reducing drug lags.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.b21-00898</identifier><identifier>PMID: 35370272</identifier><language>eng</language><publisher>Japan: The Pharmaceutical Society of Japan</publisher><subject>Committees ; Drug Approval ; Drug development ; drug lag ; drug price ; Drugs ; first-in-class drug ; Government policy ; Humans ; Japan ; me-too drug ; multi-regional clinical trial ; Multiple regression analysis ; Multivariate Analysis ; Statistical analysis ; Time Factors ; United States</subject><ispartof>Biological and Pharmaceutical Bulletin, 2022/04/01, Vol.45(4), pp.477-482</ispartof><rights>2022 The Pharmaceutical Society of Japan</rights><rights>Copyright Japan Science and Technology Agency 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4828-819736d40cdb28b51c07aacf6dcb23f805c684d67193e460d7f531a3704dd58b3</citedby><cites>FETCH-LOGICAL-c4828-819736d40cdb28b51c07aacf6dcb23f805c684d67193e460d7f531a3704dd58b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35370272$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miyazaki, Takayuki</creatorcontrib><creatorcontrib>Komiyama, Michiyuki</creatorcontrib><creatorcontrib>Matsumaru, Naoki</creatorcontrib><creatorcontrib>Maeda, Hideki</creatorcontrib><creatorcontrib>Tsukamoto, Katsura</creatorcontrib><title>Lag Time for New Innovative, First-in-Class, Drug Approval in Japan</title><title>Biological &amp; pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>Early access to novel drugs, regardless of regional differences, is significant for patients worldwide. Although various efforts have been made to reduce the drug lag, it still exists in some regions, including Japan. In this study, we focused on the drug lag of first-in-class drugs in Japan and obtained fundamental information because we considered that first-in-class and me-too drugs are essentially different and should be treated separately. We analyzed 97 first-in-class and 176 me-too drugs in new molecular entity (NME)-approved drugs in Japan and the United States during the fiscal years between 2009 and 2019. Since government policy and the Evaluation Committee on Unapproved or Off-labeled Drugs with High Medical Needs (the Committee) have a huge impact on drug lag, we distinguished NMEs developed at the Committee’s request. First-in-class drugs were developed at the Committee’s request significantly more than the me-too drugs (p = 0.0034). Although it was not statistically significant, the approval lags were 498.0 d for first-in-class drugs and 535.0 d for me-too drugs. Multiple regression analysis showed that multi-regional clinical trial (MRCT) development strategy (p = 0.0043) and foreign origin drugs (p = 0.0072) were a reducing factor and a prolonging factor of drug lag, respectively. In conclusion, the drug lag for first-in-class drug approval was one year. Global drug development using MRCT is one of the most effective development strategies for reducing drug lags.</description><subject>Committees</subject><subject>Drug Approval</subject><subject>Drug development</subject><subject>drug lag</subject><subject>drug price</subject><subject>Drugs</subject><subject>first-in-class drug</subject><subject>Government policy</subject><subject>Humans</subject><subject>Japan</subject><subject>me-too drug</subject><subject>multi-regional clinical trial</subject><subject>Multiple regression analysis</subject><subject>Multivariate Analysis</subject><subject>Statistical analysis</subject><subject>Time Factors</subject><subject>United States</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpd0DtPwzAUBWALgWgpjKzIEgtDXfxMnLEKlIcqWMpsOY5TUqVJsJMi_j3ugw4stqX76fjqAHBN8IRQLu-zNptklCCMZSJPwJAwHiNBiTgFQ5wQiSIi5ABceL_CGMeYsnMwYIKFV0yHIJ3rJVyUawuLxsE3-w1f6rrZ6K7c2DGclc53qKxRWmnvx_DB9Us4bVsXRAXLGr7qVteX4KzQlbdXh3sEPmaPi_QZzd-fXtLpHBkuqUSSJDGLco5NnlGZCWJwrLUpotxklBUSCxNJnkcxSZjlEc7jQjCiw6Y8z4XM2Ajc7XPD_1-99Z1al97YqtK1bXqvaMSjhFOMWaC3_-iq6V0dttspIjiVIii0V8Y13jtbqNaVa-1-FMFq264K7arQrtq1G_zNIbXP1jY_6r86A0j3YOU7vbRHoF1Xmsru4rhQfHscY49T86mdsjX7BWBFiiQ</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Miyazaki, Takayuki</creator><creator>Komiyama, Michiyuki</creator><creator>Matsumaru, Naoki</creator><creator>Maeda, Hideki</creator><creator>Tsukamoto, Katsura</creator><general>The Pharmaceutical Society of Japan</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20220401</creationdate><title>Lag Time for New Innovative, First-in-Class, Drug Approval in Japan</title><author>Miyazaki, Takayuki ; Komiyama, Michiyuki ; Matsumaru, Naoki ; Maeda, Hideki ; Tsukamoto, Katsura</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4828-819736d40cdb28b51c07aacf6dcb23f805c684d67193e460d7f531a3704dd58b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Committees</topic><topic>Drug Approval</topic><topic>Drug development</topic><topic>drug lag</topic><topic>drug price</topic><topic>Drugs</topic><topic>first-in-class drug</topic><topic>Government policy</topic><topic>Humans</topic><topic>Japan</topic><topic>me-too drug</topic><topic>multi-regional clinical trial</topic><topic>Multiple regression analysis</topic><topic>Multivariate Analysis</topic><topic>Statistical analysis</topic><topic>Time Factors</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyazaki, Takayuki</creatorcontrib><creatorcontrib>Komiyama, Michiyuki</creatorcontrib><creatorcontrib>Matsumaru, Naoki</creatorcontrib><creatorcontrib>Maeda, Hideki</creatorcontrib><creatorcontrib>Tsukamoto, Katsura</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biological &amp; pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyazaki, Takayuki</au><au>Komiyama, Michiyuki</au><au>Matsumaru, Naoki</au><au>Maeda, Hideki</au><au>Tsukamoto, Katsura</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lag Time for New Innovative, First-in-Class, Drug Approval in Japan</atitle><jtitle>Biological &amp; pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>45</volume><issue>4</issue><spage>477</spage><epage>482</epage><pages>477-482</pages><artnum>b21-00898</artnum><issn>0918-6158</issn><eissn>1347-5215</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Early access to novel drugs, regardless of regional differences, is significant for patients worldwide. Although various efforts have been made to reduce the drug lag, it still exists in some regions, including Japan. In this study, we focused on the drug lag of first-in-class drugs in Japan and obtained fundamental information because we considered that first-in-class and me-too drugs are essentially different and should be treated separately. We analyzed 97 first-in-class and 176 me-too drugs in new molecular entity (NME)-approved drugs in Japan and the United States during the fiscal years between 2009 and 2019. Since government policy and the Evaluation Committee on Unapproved or Off-labeled Drugs with High Medical Needs (the Committee) have a huge impact on drug lag, we distinguished NMEs developed at the Committee’s request. First-in-class drugs were developed at the Committee’s request significantly more than the me-too drugs (p = 0.0034). Although it was not statistically significant, the approval lags were 498.0 d for first-in-class drugs and 535.0 d for me-too drugs. Multiple regression analysis showed that multi-regional clinical trial (MRCT) development strategy (p = 0.0043) and foreign origin drugs (p = 0.0072) were a reducing factor and a prolonging factor of drug lag, respectively. In conclusion, the drug lag for first-in-class drug approval was one year. Global drug development using MRCT is one of the most effective development strategies for reducing drug lags.</abstract><cop>Japan</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>35370272</pmid><doi>10.1248/bpb.b21-00898</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0918-6158
ispartof Biological and Pharmaceutical Bulletin, 2022/04/01, Vol.45(4), pp.477-482
issn 0918-6158
1347-5215
language eng
recordid cdi_proquest_miscellaneous_2646942003
source Free Full-Text Journals in Chemistry
subjects Committees
Drug Approval
Drug development
drug lag
drug price
Drugs
first-in-class drug
Government policy
Humans
Japan
me-too drug
multi-regional clinical trial
Multiple regression analysis
Multivariate Analysis
Statistical analysis
Time Factors
United States
title Lag Time for New Innovative, First-in-Class, Drug Approval in Japan
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T22%3A35%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lag%20Time%20for%20New%20Innovative,%20First-in-Class,%20Drug%20Approval%20in%20Japan&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=Miyazaki,%20Takayuki&rft.date=2022-04-01&rft.volume=45&rft.issue=4&rft.spage=477&rft.epage=482&rft.pages=477-482&rft.artnum=b21-00898&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.b21-00898&rft_dat=%3Cproquest_cross%3E2646942003%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4828-819736d40cdb28b51c07aacf6dcb23f805c684d67193e460d7f531a3704dd58b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2646154285&rft_id=info:pmid/35370272&rfr_iscdi=true